Search

Displaying results 551 - 560 of 595 in total
  1. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid . In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with br...

  2. Drug

    Multipotent adult arogenitor cells

    go.drugbank.com/drugs/DB15742
    Investigational

    After administration, the cells are cleared from the body over time. Currently, MultiStem is being investigated against neurological, inflammatory, immune, and cardiovascular diseases and conditions.

  3. Drug

    ATX-101

    go.drugbank.com/drugs/DB05780
    Investigational

    ATX-101 demonstrates a relative selectivity for fat over other tissues.

  4. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability.

  5. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  6. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps the only viable option for reversing the anticoagulant effect of heparin use for over

  7. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.

  8. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    The unrelated donor transplant setting has several advantages over related donor transplant and bone marrow transplantation; it allows shorter time to transplant and tolerance of 1–2 human leukocyte antigen

  9. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    [L45793,L43130] For over a decade, bevacizumab was also used off-label by intravitreal injection to treat neovascular (wet) age-related macular degeneration and other retinal conditions, repackaged from

  10. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229708] Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed.